



Mucosis to Present at World Vaccines Congress 2016

Groningen, the Netherlands, 29 March, 2016 – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation and needle-free human vaccines for infectious diseases, will present key data tomorrow at the 16th annual World Vaccines Congress US. The event is taking place from today until 31 March in Washington D.C., USA. This will be the 2nd year running that Mucosis has presented at the event.

Mucosis' Co-founder and Chief Scientific Officer, Dr. Kees Leenhouts will be discussing progress with Mucosis' lead vaccine candidate, SynGEM[®], a needle-free vaccine for the prevention of Respiratory Syncytial Virus (RSV). Mucosis received a 5 million Euro award from the Dutch government for the development of SynGEM[®] and recently secured a £2.77 million (Euro 3.60 million) [translational fund award](#) from the Wellcome Trust to further support the vaccine clinical program.

The vaccine uses Mucosis' proprietary needle-free platform technology that enables vaccines to be delivered nasally, eliciting an immune response from the mucosal linings of the airways, as well as a systemic immune response in the rest of the body. This dual route of protection holds the promise to provide a more robust barrier to disease, as it combines preventing entry of the pathogen at the first line of defense; the mucosal barriers, with protection at the humoral level. The recent work of the group of prof. Openshaw at Imperial College London has demonstrated the possible relevance of mucosal IgA antibodies in the protection against the airway pathogen RSV¹.

Dr. Leenhouts will be presenting data on the development of Mucosis' intranasal RSV vaccine, SynGEM[®]. Its unique presentation allows SynGEM to elicit powerful neutralizing serum antibodies as well as secreted mucosal IgA antibodies in the respiratory tract.

"In addition to its dual action, the RSV F antigen in SynGEM[®] has important immunogenic characteristics including the presentation of prefusion F-specific epitopes. The prefusion F antigen is recognised as a key area of research in developing an effective vaccine for RSV, due to its ability to induce highly potent antibodies against the RSV pathogen," Dr. Leenhouts commented. "Developing an F-type RSV subunit vaccine is challenging as the natural prefusion form of the antigen is inherently unstable. Mucosis has overcome this challenge with SynGEM[®], which will be entering first-in-human studies in 2016."

Dr. Leenhouts will be presenting at 11.40 am Eastern Time as part of the influenza and respiratory stream on Wednesday 30 March.

¹ Habibi et al. Am J Respir Crit Care Med., 1 May 2015

-Ends-

Note for Editors

About Mucosis www.mucosis.com

Mucosis B.V. (Mucosis) is a clinical-stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases. Mucosis's investigational patient-friendly vaccines can be delivered via the nose or mouth to elicit a more natural immune response with a broader base of protection. The company is developing multiple programs for its clinical-stage proprietary Mimopath[®]

platform vaccine technology for several routes of administration including those that provide additional mucosal protection, where over 90% of pathogens enter the human body.

Mucosis's lead product SynGEM[®], a stabilized recombinant vaccine delivered intranasally to prevent respiratory syncytial virus (RSV) infection, will enter human proof-of-concept studies in 2016. The annual global burden of RSV illness is significant. Nair *et al.* (Lancet, 16 April 2010) estimated that in 2005 there were up to 33.8 million new episodes of RSV-associated acute lower respiratory infection (ALRI) worldwide in children under 5, and over 3.4 million hospital admissions associated with severe RSV-associated ALRI disease. Global mortality was estimated at 66,000 to 199,000 children younger than 5 years having died from RSV-associated ALRI in 2005.

The company has also developed PneuGEM[®], a vaccine to prevent diseases caused by pneumococcal bacteria, and FluGEM[®], a vaccine against influenza. FluGEM[®] served as a successful proof of concept for the Mimopath[®] platform in human clinical testing.

Mucosis has raised over EUR 20m in dilutive and non-dilutive funding, with key investment partners including MedSciences, BioGeneration, NOM & Utrecht Holdings. The company has strategic partnerships in US, Asia and the EU with organisations including the US National Institutes of Health, China-based Changchun BCHT Biotechnology co., Utrecht University, and the Netherlands Enterprise Agency. Mucosis's management is highly experienced in the design, development and commercialisation of vaccines. Mucosis employs over 10 staff at its headquarters in Groningen, The Netherlands.

US Media Enquiries: Lazar Partners	EU Media Enquiries: Instinctif Partners
Fern Lazar/Danielle Lewis/Rob Sawyer US: +1.212.867.1762 mucosis@lazarpartners.com	Sue Charles/Daniel Gooch/Alex Bannister UK: +44 (0) 20 7866 7905 mucosis@instinctif.com